133 results found.

Ovarian Cancer Clinical Trial using MK-1775; Placebo; paclitaxel; carboplatin

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Randomized, Phase II Study Evaluating MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Adult Patients With Platinum Sensitive p53 Mutant Ovarian Cancer.
MK-1775; Placebo; paclitaxel; carboplatin

Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Clinical Trial

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers.

Sexual Dysfunctions, Psychological, Uterine Cervical Neoplasms, O Clinical Trial using GyneGals Support Group

Women's College Hospital - Recruiting 18 years or older.
- A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer.
GyneGals Support Group

Ovarian Cancer Clinical Trial using IMAB027

Ganymed Pharmaceuticals AG - Recruiting 18 years or older.
- A First-in-human Dose Escalation and Dose Finding Phase 1/2 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR).
IMAB027

Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adeno Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; carboplatin; bevacizumab; laboratory biomarker analysis

Mixed Muellerian Cancer, Cervical Cancer, Ovarian Cancer, Breast Clinical Trial using Carboplatin; Olaparib; Treatment Effect

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Pharmacokinetic/Pharmacodynamic Study With a Phase I Run-In With a PARP Inhibitor (Olaparib) in Combination With Carboplatin for Refractory or Recurrent Women's Cancers.
Carboplatin; Olaparib; Treatment Effect

Ovarian Cancer Clinical Trial

Genentech - Recruiting 18 years or older.
- Patient Reported Symptoms in Ovarian Cancer.

Non-Small Cell Lung Cancer, Ovarian Cancer Clinical Trial using DNIB0600A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer.
DNIB0600A

Ovarian Cancer, Pancreatic Cancer Clinical Trial using DMUC5754A

Genentech - Recruiting 18 years or older.
- A Phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer.
DMUC5754A

Ovarian Cancer Clinical Trial using DNIB0600A; carboplatin; bevacizumab [Avastin]

Genentech - Recruiting 18 years or older.
- A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer.
DNIB0600A; carboplatin; bevacizumab [Avastin]

Ovarian Cancer, Epithelial Tumors, Malignant, Fallopian Tube Canc Clinical Trial using DNIB0600A; pegylated liposomal doxorubicin

Genentech - Recruiting 18 years or older.
- A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY AND ACTIVITY OF DNIB0600A COMPARED TO PEGYLATED LIPOSOMAL DOXORUBICIN ADMINISTERED INTRAVENOUSLY TO PATIENTS WITH PLATINUM-RESISTANT OVARIAN CANCER.
DNIB0600A; pegylated liposomal doxorubicin

Ovarian Cancer, Pancreatic Cancer Clinical Trial using DMOT4039A

Genentech - Recruiting 18 years or older.
- A Phase I, Open Label Study of the Safety and Pharmacokinetics of Escalating Doses of DMOT4039A in Patients With Unresectable Pancreatic or Platinum Resistant Ovarian Cancer.
DMOT4039A

Childhood Germ Cell Tumor, Ovarian Cancer, or Teratoma Clinical Trial using carboplatin; etoposide; ifosfamide; paclitaxel; thiotepa; autologous hematopoietic stem cell transplantation; Mesna; filgrastim

Masonic Cancer Center, University of Minnesota - Recruiting 10 years to 69 years.
- Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors.
carboplatin; etoposide; ifosfamide; paclitaxel; thiotepa; autologous hematopoietic stem cell transplantation; Mesna; filgrastim

Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Clinical Trial

Cancer Centre of Monoclonal Therapy, LLC - Recruiting 18 years or older.
- Prognostic Potential of Cell Surface Markers and Pim Kinases in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors.

Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, or Fol Clinical Trial using Olaparib 300mg tablets; Placebo to match olaparib 300mg

AstraZeneca - Recruiting 18 years or older.
- Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy.
Olaparib 300mg tablets; Placebo to match olaparib 300mg

Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Clinical Trial using Olaparib 300mg tablets

AstraZeneca - Recruiting 18 years or older.
- A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy..
Olaparib 300mg tablets

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Prospective, Longitudinal Study of YKL-40 in Patients With FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy.
laboratory biomarker analysis

Ovarian Stromal Cancer Clinical Trial using paclitaxel; carboplatin; bleomycin sulfate; etoposide phosphate; cisplatin

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced State and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary.
paclitaxel; carboplatin; bleomycin sulfate; etoposide phosphate; cisplatin

Ovarian Carcinosarcoma, Recurrent Ovarian Epithelial Cancer, Recu Clinical Trial using paclitaxel; carboplatin; ifosfamide

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
paclitaxel; carboplatin; ifosfamide

Ovarian Carcinoma Clinical Trial using Ovarian Cancer Screening; Prophylactic Salpingectomy with Delayed Oophorectomy; Risk-Reducing Salpingo-Oophorectomy; Questionnaire; Transvaginal Ultrasound; Phone Call

M.D. Anderson Cancer Center - Recruiting 35 years to 46 years.
- Prophylactic Salpingectomy With Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study.
Ovarian Cancer Screening; Prophylactic Salpingectomy with Delayed Oophorectomy; Risk-Reducing Salpingo-Oophorectomy; Questionnaire; Transvaginal Ultrasound; Phone Call

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?.
behavioral dietary intervention; exercise intervention; counseling intervention; educational intervention; compliance monitoring; questionnaire administration; quality-of-life assessment; laboratory biomarker analysis

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using elesclomol sodium; paclitaxel

Gynecologic Oncology Group - Recruiting 18 years or older.
- A PHASE II EVALUATION OF ELESCLOMOL SODIUM AND WEEKLY PACLITAXEL IN THE TREATMENT OF RECURRENT OR PERSISTENT PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
elesclomol sodium; paclitaxel

Oncology, BRCA Mutated, High Grade Serous Ovarian Cancer, or BRCA Clinical Trial using Veliparib

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors.
Veliparib

Stage I Ovarian Epithelial Cancer, Stage I Primary Peritoneal Cav Clinical Trial using pharmacological study; questionnaire administration; assessment of therapy complications; quality-of-life assessment; carboplatin; paclitaxel; filgrastim

Gynecologic Oncology Group - Recruiting 75 years or older.
- Chemotherapy Toxicity in Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
pharmacological study; questionnaire administration; assessment of therapy complications; quality-of-life assessment; carboplatin; paclitaxel; filgrastim

Biochemical-recurrent Only Epithelial Ovarian Cancer, Primary Per Clinical Trial using INCB024360; tamoxifen

Incyte Corporation - Recruiting 18 years or older.
- A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy.
INCB024360; tamoxifen

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Roswell Park Cancer Institute - Recruiting 18 years or older.
- A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing ALVAC(2)-NY-ESO-1(M)/TRICOM Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; sirolimus; laboratory biomarker analysis; sargramostim

Ovarian Cancer Clinical Trial using pertuzumab; placebo; chemotherapy

Hoffmann-La Roche - Recruiting 18 years or older.
- A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND, MULTICENTER TRIAL ASSESSING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY VS. PLACEBO PLUS STANDARD CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER AND LOW HER3 mRNA EXPRESSION.
pertuzumab; placebo; chemotherapy

Ovarian Cancer Clinical Trial using bevacizumab [Avastin]; Carboplatin; paclitaxel

Hoffmann-La Roche - Recruiting 18 years or older.
- A Randomized, Open-label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable..
bevacizumab [Avastin]; Carboplatin; paclitaxel

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

VentiRx Pharmaceuticals Inc. - Recruiting 18 years or older.
- A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
pegylated liposomal doxorubicin (PLD); VTX-2337; Placebo

Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Clinical Trial using Oral rucaparib

Clovis Oncology, Inc. - Recruiting 18 years or older.
- A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2).
Oral rucaparib

Ovarian Cancer, Cancer of the Ovary, or Ovarian Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Collection of Blood From Patients With Ovarian Cancer.

Advanced Ovarian Cancer, Primary Peritoneal Cancer, Advanced Brea Clinical Trial using BMN 673

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations.
BMN 673

Ovarian Cancer, or Endometrial Cancer Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 50 years or older.
- Assessment of Screening Modalities for Gynecologic Cancers.

Metastatic Cancer, Metastatic Melanoma, Renal Cancer, Colorectal Clinical Trial using Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years.
- Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes.
Anti-VEGFR2 CAR CD8 plus PBL; Cyclophosphamide; Aldesleukin; Fludarabine

Pleuropulmonary Blastoma, Cystic Nephroma, Ovarian Sertoli-Leydig Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Dicer1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study.

Ovarian Cancer Clinical Trial

Eventus Diagnostics Ltd - Recruiting 18 years or older.
- Blood Test for Ovarian Cancer Associated Auto Antibodies.

Breast Cancer, or Ovarian Cancer Clinical Trial using AZ2281; Carboplatin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- A Phase I Study With an Expansion Cohort of the PARP Inhibitor AZD2281 Combined With Carboplatin in BRCA1/2 Familial Breast and Ovarian Cancer and Sporadic Triple Negative Breast and Ovarian Cancer.
AZ2281; Carboplatin

Fallopian Tube Cancer, Ovarian Cancer, or Peritoneal Cancer Clinical Trial using AMG 386; Paclitaxel; AMG 386 Placebo; Carboplatin

Amgen - Recruiting 18 years or older.
- A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers.
AMG 386; Paclitaxel; AMG 386 Placebo; Carboplatin

Metastatic Cancer, Pancreatic Cancer, Mesothelioma, Ovarian Cance Clinical Trial using Fludarabine; Cycolphosphamide; Aldesleukin

National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 70 years.
- Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes.
Fludarabine; Cycolphosphamide; Aldesleukin

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Carc Clinical Trial using Tivozanib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Tivozanib

Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Can Clinical Trial using Tivozanib

Northwestern University - Recruiting 18 years or older.
- The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Tivozanib

Ovarian Neoplasms, Peritoneal Neoplasms, or Fallopian Tube Neopla Clinical Trial using Trabectedin; DOXIL; Dexamethasone

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
Trabectedin; DOXIL; Dexamethasone

Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, or Peri Clinical Trial using carboplatin; cisplatin; paclitaxel; quality-of-life assessment

NCIC Clinical Trials Group - Recruiting 18 years or older.
- A Phase II/III Study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin Plus Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy.
carboplatin; cisplatin; paclitaxel; quality-of-life assessment

Stage III Ovarian Cancer, or Stage IV Ovarian Cancer Clinical Trial using Vaccine: FANGT Vaccine; Carboplatinum; Carboplatinum and Taxol; FANG

Gradalis, Inc. - Recruiting 18 years or older.
- Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANGT) Integrated With Chemotherapy for Patients With Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study CL-PTL 105.
Vaccine: FANGT Vaccine; Carboplatinum; Carboplatinum and Taxol; FANG

Relapsed Epithelial Ovarian Cancer, Relapsed Primary Peritoneal C Clinical Trial using Birinapant; Conatumumab

TetraLogic Pharmaceuticals - Recruiting 18 years or older.
- A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer.
Birinapant; Conatumumab

Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial C Clinical Trial using IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 19 years or older.
- A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma.
IDO1 inhibitor INCB024360; therapeutic conventional surgery; laboratory biomarker analysis

Fallopian Tube, Primary Peritoneal Cancer, or Solid Tumors (eg Br Clinical Trial using ABT-767

AbbVie - Recruiting 18 years or older.
- A Phase 1 Study of ABT-767 in BRCA1 or BRCA2 Mutation Carriers With Advanced Solid Tumors and in Subjects With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
ABT-767

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using Rucaparib

Clovis Oncology, Inc. - Recruiting 18 years or older.
- A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor.
Rucaparib

Breast Cancer, or Hereditary Breast/Ovarian Cancer (brca1, brca2) Clinical Trial using counseling intervention; educational intervention; survey administration; psychosocial assessment and care; supportive care

Georgetown University - Recruiting 8 years or older.
- Parent Communication Study II - Randomized Controlled Trial of Decision Support vs. Education for Parent Communication of BRCA 1/2 Cancer Genetic Test Results to Children.
counseling intervention; educational intervention; survey administration; psychosocial assessment and care; supportive care

Ovarian, Fallopian, and Primary Peritoneal Cancer Clinical Trial using Daily stress reduction program; Attention control

University of Wisconsin, Madison - Recruiting 18 years or older.
- Stress Reduction During Primary Adjuvant Chemotherapy for Ovarian Cancer.
Daily stress reduction program; Attention control

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer.
veliparib; pegylated liposomal doxorubicin hydrochloride; pharmacological study; laboratory biomarker analysis

Ovarian Cancer Clinical Trial using Nutritional Counseling; Daily Supplements

M.D. Anderson Cancer Center - Recruiting 21 years or older.
- A Randomized Phase II Study of the Nutritional Supplements Juice Plus + and Juice Plus + Complete in Ovarian Cancer Patients.
Nutritional Counseling; Daily Supplements

Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystaden Clinical Trial using paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912).
paclitaxel; docetaxel; carboplatin; bevacizumab; gemcitabine hydrochloride; laboratory biomarker analysis; quality-of-life assessment

Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Clinical Trial using veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I/II Trial of ABT-888, an Inhibitor of Poly (ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed or Refractory Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy.
veliparib; topotecan hydrochloride; pharmacogenomic studies; pharmacological study; laboratory biomarker analysis

Ovarian Cancer, or Breast Cancer Clinical Trial using BKM120 and Olaparib

Dana-Farber Cancer Institute - Recruiting 18 years or older.
- Phase I Study of the Oral PI3kinase Inhibitor BKM120 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or Recurrent High Grade Serous Ovarian Cancer.
BKM120 and Olaparib

Platinum Sensitive Ovarian Cancer Clinical Trial using Active comparator: Niraparib; placebo

Tesaro, Inc. - Recruiting 18 years or older.
- A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer..
Active comparator: Niraparib; placebo

Oral Contraceptive Clinical Trial using Oral Contraceptive: Ortho-Novumr 1/35; Oral Contraceptive: Ovconr 35; Oral Contraceptive: Microgestin Fer 1/20

University of Southern California - Recruiting 18 years to 35 years.
- The Effects of Dose and Formulation of Oral Contraceptives (OCs) on Breast-Cell Proliferation: Can the Chemopreventive Effects of OCs on Endometrial and Ovarian Cancer be Extended to Breast Cancer?.
Oral Contraceptive: Ortho-Novumr 1/35; Oral Contraceptive: Ovconr 35; Oral Contraceptive: Microgestin Fer 1/20

Metastatic Ovarian Cancer Clinical Trial using Experimental arm

Centre Val d'Aurelle - Paul Lamarque - Recruiting 18 years or older.
- Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring.
Experimental arm

Male Breast Cancer, Recurrent Melanoma, Stage IV Breast Cancer, S Clinical Trial using propranolol hydrochloride; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Pilot Study of Beta-Blockers in Patients With Advanced Cancer.
propranolol hydrochloride; Correlative Studies

Ovarian Cancer Clinical Trial using Palliative Performance Scale version 2 (PPSv2); McCorkle Symptom Distress Scale (SDS); Geriatric Assessment; Medical Records Abstraction

UNC Lineberger Comprehensive Cancer Center - Recruiting 65 years or older.
- Use of Palliative Performance and Symptom Distress Scales in Older Patients With Advanced Ovarian Cancer.
Palliative Performance Scale version 2 (PPSv2); McCorkle Symptom Distress Scale (SDS); Geriatric Assessment; Medical Records Abstraction

Male Breast Cancer, Recurrent Breast Cancer, Recurrent Fallopian Clinical Trial using mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

University of Chicago - Recruiting 18 years or older.
- Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer.
mifepristone; carboplatin; gemcitabine hydrochloride; laboratory biomarker analysis; pharmacological study

Ovarian Cancer Clinical Trial using Ipilimumab

Bristol-Myers Squibb - Recruiting 18 years or older.
- A Phase II Safety and Efficacy Study of Ipilimumab Monotherapy Following Completion of Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer Subjects With Residual Measurable Disease.
Ipilimumab

Epithelial Ovarian Cancer Clinical Trial using Placebo Study Agent; Cvac

Prima BioMed Ltd - Recruiting 18 years or older.
- A Randomized, Double-Blinded, Placebo-Controlled Trial of Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-Line Chemotherapy (Australia and United States) / A Randomized Trial of Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-Line Chemotherapy or Following Second-Line Treatment (EU and EEU).
Placebo Study Agent; Cvac

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Canc Clinical Trial using CRLX101

Massachusetts General Hospital - Recruiting 18 years or older.
- A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer.
CRLX101

Ovarian Cancer Clinical Trial using Questionnaire; Interview

M.D. Anderson Cancer Center - Recruiting 18 years or older.
- Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer.
Questionnaire; Interview

Ovarian Cancer, Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer.

Peritoneal Neoplasms Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Ovarian Cancer Clinical Trial

Hoffmann-La Roche - Recruiting 18 years or older.
- AN OBSERVATIONAL STUDY OF AVASTINr (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER.

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC #761968 IND #116059) VERSUS WEEKLY PACLITAXEL (NSC #673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
cabozantinib-s-malate; paclitaxel; laboratory biomarker analysis

Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer, Squam Clinical Trial using OPB-111001

Otsuka Novel Products GmbH - Recruiting 18 years or older.
- A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment.
OPB-111001

Epithelial Ovarian Cancer Clinical Trial using CAELYX; Topotecan HCl

Xian-Janssen Pharmaceutical Ltd. - Recruiting 18 years or older.
- A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYXr Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy.
CAELYX; Topotecan HCl

Ovarian Epithelial Cancer, Carcinoma in Situ, or Ovarian Cancer Clinical Trial using Lavage of the Cavum uteri and proximal Fallopian tubes

Medical University of Vienna - Recruiting 18 years to 80 years.
- Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma.
Lavage of the Cavum uteri and proximal Fallopian tubes

Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Can Clinical Trial using wild-type reovirus; paclitaxel

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A RANDOMIZED PHASE II EVALUATION OF WEEKLY PACLITAXEL (NSC# 673089) VERSUS WEEKLY PACLITAXEL WITH ONCOLYTIC REOVIRUS (REOLYSIN NSC # 729968, BB-IND #13370) IN THE TREATMENT OF RECURRENT OR PERSISTENT OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
wild-type reovirus; paclitaxel

Breast Cancer, Cancer Survivor, Cognitive/Functional Effects, or Clinical Trial using cognitive intervention; questionnaire administration; quality-of-life assessment; blood-oxygen-level-dependent functional magnetic resonance imaging; memory intervention

University of Washington - Recruiting 21 years to 90 years.
- Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study..
cognitive intervention; questionnaire administration; quality-of-life assessment; blood-oxygen-level-dependent functional magnetic resonance imaging; memory intervention

Breast Neoplasms, or Ovarian Neoplasms Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 18 years or older.
- Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer.

Ovarian Cancer Clinical Trial using Paclitaxel + Carboplatin every 3 weeks; Carboplatin monotherapy every 3 weeks; Weekly Paclitaxel and Carboplatin

Hospices Civils de Lyon - Recruiting 70 years or older.
- EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer.
Paclitaxel + Carboplatin every 3 weeks; Carboplatin monotherapy every 3 weeks; Weekly Paclitaxel and Carboplatin

Melanoma, Ovarian Cancer, Renal Cell Cancer, or Non-small Cell Lu Clinical Trial using IDC-G305

Immune Design - Recruiting 18 years to 80 years.
- A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer.
IDC-G305

Ovarian Cancer Recurrent Clinical Trial using Lenalidomide

ARCAGY/ GINECO GROUP - Recruiting 18 years or older.
- A Two Stage Trial of l‚nalidomide (Revlimidr) : a Phase II Study of l‚nalidomide as Single Agent in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse: Followed by a Phase I of l‚nalidomide in Combination With Carboplatin and Liposomal Pegylated Doxorubicin..
Lenalidomide

Epithelial Ovarian Cancer Clinical Trial using Bevacizumab

ARCAGY/ GINECO GROUP - Recruiting 18 years or older.
- Non Interventional Study Dealing With the Use of Bevacizumab (Avastinr) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy.
Bevacizumab

Ovarian Cancer Clinical Trial using carboplatin and liposomal doxorubicin

ARCAGY/ GINECO GROUP - Recruiting 18 years or older.
- Phase Ib / II Trial Evaluating the Association Myocet r - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum.
carboplatin and liposomal doxorubicin

Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Clinical Trial using Veliparib (ABT-888); Placebo

AbbVie - Recruiting 18 years or older.
- A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors.
Veliparib (ABT-888); Placebo

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using Rucaparib; Placebo

Clovis Oncology, Inc. - Recruiting 18 years or older.
- Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3).
Rucaparib; Placebo

Platinum Resistant Ovarian Cancer Clinical Trial using Paclitaxel

Vascular Biogenics Ltd. operating as VBL Therapeutics - Recruiting 18 years or older.
- A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Mllerian Cancer.
Paclitaxel

Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Ca Clinical Trial using veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

University of Washington - Recruiting 18 years or older.
- Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer.
veliparib; cisplatin; vinorelbine tartrate; laboratory biomarker analysis; pharmacological study

Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Perito Clinical Trial using Narrow Band Imaging (NBI)

Memorial Sloan-Kettering Cancer Center - Recruiting 19 years or older.
- Narrow Band Imaging (NBI): A Novel Imaging Modality in Minimally Invasive.
Narrow Band Imaging (NBI)

Ovarian Cancer, Fallopian Tubes Cancer, or Peritoneal Cancer Clinical Trial using Secondary Cytoreductive Surgery; Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC); platinum-based systemic chemotherapy postoperatively

Memorial Sloan-Kettering Cancer Center - Recruiting 21 years or older.
- A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Secondary Cytoreductive Surgery; Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC); platinum-based systemic chemotherapy postoperatively

Ovarian Cancer Clinical Trial using EC145; Pegylated Liposomal Doxorubicin (PLD/Doxilr/Caelyxr); placebo; EC20

Merck Sharp & Dohme Corp. - Recruiting 18 years or older.
- A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxilr/Caelyxr) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer.
EC145; Pegylated Liposomal Doxorubicin (PLD/Doxilr/Caelyxr); placebo; EC20

Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hered Clinical Trial using laboratory biomarker analysis; screening questionnaire administration; study of high risk factors

Northwestern University - Recruiting 18 years to 80 years.
- Northwestern Ovarian Cancer Early Detection & Prevention Program: A Specimen and Data Study.
laboratory biomarker analysis; screening questionnaire administration; study of high risk factors

Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystade Clinical Trial using paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I STUDY OF INTRAVENOUS CARBOPLATIN/PACLITAXEL OR INTRAVENOUS AND INTRAPERITONEAL PACLITAXEL/CISPLATIN IN COMBINATION WITH CONTINUOUS OR INTERMITTENT/ CTEP-SUPPLIED AGENT ABT-888 (NSC #737664) AND CTEP-SUPPLIED AGENT BEVACIZUMAB (NSC #704865) IN NEWLY DIAGNOSED PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER.
paclitaxel; carboplatin; bevacizumab; veliparib; laboratory biomarker analysis

Stage IIIC Ovarian Cancer Clinical Trial using Laparoscopy; Cytoreduction

Catholic University of the Sacred Heart - Recruiting 18 years to 75 years.
- Surgical Complications Related to Primary or Interval Debulking in Ovarian Neoplasm.
Laparoscopy; Cytoreduction

Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer Clinical Trial using TroVaxr; Placebo

University College, London - Recruiting 18 years or older.
- A Randomised Parallel Group Double-Blind Phase II Study to Assess the Activity of TroVaxr (MVA-5T4) Versus Placebo in Patients With Relapsed Asymptomatic Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
TroVaxr; Placebo

Ewing's Sarcoma, or Ovarian Cancer Clinical Trial using FANG

Gradalis, Inc. - Recruiting 12 years or older.
- Phase I Trial of Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer.
FANG

Ovarian Cancer, Peritoneal Cavity Cancer, or Unspecified Adult So Clinical Trial using paclitaxel albumin-stabilized nanoparticle formulation; liquid chromatography; mass spectrometry; pharmacological study; laboratory biomarker analysis

City of Hope Medical Center - Recruiting 19 years or older.
- Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity.
paclitaxel albumin-stabilized nanoparticle formulation; liquid chromatography; mass spectrometry; pharmacological study; laboratory biomarker analysis

Malignant Pleural Effusion, Lung Cancer, Mesothelioma, Breast Can Clinical Trial using AdV-tk + valacyclovir

Advantagene, Inc. - Recruiting 18 years or older.
- A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion.
AdV-tk + valacyclovir

Ovarian Cancer Clinical Trial

Hellenic Oncology Research Group - Recruiting 18 years or older.
- A Multicentre, Observational Study of Bevacizumab (Avastin) Added to Front-line Chemotherapy in Patients With Stage IIIb, IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma in Routine Clinical Practice..

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using paclitaxel poliglumex; clinical observation; paclitaxel

Gynecologic Oncology Group - Recruiting N/A or older.
- A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND #70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
paclitaxel poliglumex; clinical observation; paclitaxel

Recurrent Platinum-sensitive Ovarian Cancer Clinical Trial using Carboplatin; PLD; Bevacizumab

AGO Research GmbH - Recruiting 18 years or older.
- A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer.
Carboplatin; PLD; Bevacizumab

Epithelial Ovarian Cancer Clinical Trial using FES-PET

University Medical Centre Groningen - Recruiting 18 years or older.
- Feasibility Study: FES-PET to Determine ER-expression in Epithelial Ovarian Cancer.
FES-PET

Ovarian Cancer Clinical Trial using FANG; standard of care observational follow-up

Gradalis, Inc. - Recruiting 18 years or older.
- Randomized Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANGT) for High Risk Stage III/IV Ovarian Cancer.
FANG; standard of care observational follow-up

Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peri Clinical Trial using Acute Normovolemic Hemodilution

Memorial Sloan-Kettering Cancer Center - Recruiting 18 years to 69 years.
- A Pilot Study of Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer.
Acute Normovolemic Hemodilution

Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian End Clinical Trial using bortezomib; carboplatin; pharmacological study

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A PHASE I PHARMACOKINETIC STUDY OF INTRAPERITONEAL CTEP-SUPPLIED AGENT BORTEZOMIB (PS-341, NSC 681239, IND# 58443) AND CARBOPLATIN (NSC# 241240) IN PATIENTS WITH PERSISTENT OR RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER.
bortezomib; carboplatin; pharmacological study

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Gynecologic Oncology Group - Recruiting 18 years or older.
- A Phase I Study of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered in Combination With Pegylated Liposomal Doxorubicin (PLD, Doxil (NSC #712227 or Lipodox) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
EGEN-001; pegylated liposomal doxorubicin hydrochloride; RNA analysis; laboratory biomarker analysis

Ovarian Cancer Clinical Trial using Panitumumab; pegylated liposomal doxorubicin (PLD); Carboplatin; Gemcitabine

WiSP Wissenschaftlicher Service Pharma GmbH - Recruiting 18 years or older.
- PROVE A Randomized Phase II Trial of Standard Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer.
Panitumumab; pegylated liposomal doxorubicin (PLD); Carboplatin; Gemcitabine

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; ifosfamide; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years to 65 years.
- A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY.
carboplatin; ifosfamide; hyperthermia treatment

Ovarian Cancer Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin

National Cancer Institute, Naples - Recruiting 18 years or older.
- A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS.
Bevacizumab; Paclitaxel; Carboplatin

Adenocarcinoma of the Ovary Clinical Trial using OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine

AVAX Technologies - Recruiting 18 years or older.
- OVaxr: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse.
OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Canc Clinical Trial using Alvimopan; Placebo

Mayo Clinic - Recruiting 18 years or older.
- Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial.
Alvimopan; Placebo

Ovarian Cancer Clinical Trial using T cells

Adaptimmune - Recruiting 18 years or older.
- A Phase I/IIa, Open Label, Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY ESO 1/LAGE-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer.
T cells

brca1 Mutation Carrier, brca2 Mutation Carrier, Breast Cancer, or Clinical Trial using letrozole

UNICANCER - Recruiting 40 years to 69 years.
- Prevention of Breast Cancer by Letrozole in Post-menopausal Women Carrying a BRCA1/BRCA2 Mutation.
letrozole

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clinical Trial using Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Masonic Cancer Center, University of Minnesota - Recruiting 18 years or older.
- Lymphodepleting Chemotherapy and T-Cell Suppression Followed By Allogeneic Natural Killer Cells and IL-2 in Patients With Recurrent Ovarian, Fallopian Tube, Primary Peritoneal Cancer and Advanced Metastatic Breast Cancer (MT2009-30).
Fludarabine; Cyclophosphamide; Cyclosporine; Natural killer cells; IL-2; Methylprednisolone; Interleukin-2

Fallopian Tube Cancer, Ovarian Cancer, or Primary Peritoneal Cavi Clinical Trial using carboplatin; paclitaxel; pazopanib hydrochloride; laboratory biomarker analysis; pharmacological study

European Organisation for Research and Treatment of Cancer - EORTC - Recruiting 18 years or older.
- Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma.
carboplatin; paclitaxel; pazopanib hydrochloride; laboratory biomarker analysis; pharmacological study

Carcinoma of the Ovary, Fallopian Tube Cancer, or Peritoneal Sero Clinical Trial using blood samples

Centre Francois Baclesse - Recruiting 18 years or older.
- Search for Predictors of Therapeutic Response in Patients With Carcinoma of the Ovary, the Fallopian Tube or Peritoneal Serous-type Advanced.
blood samples

Ovarian Cancer, Peritoneal Cancer, or Fallopian Tube Cancer Clinical Trial using intravenous docetaxel with intraperitoneal oxaliplatin; intravenous oxaliplatin with intraperitoneal docetaxel

University of Pittsburgh - Recruiting 18 years or older.
- Phase I Dose-Escalation Parallel Studies of Intraperitoneal Oxaliplatin With Intravenous Docetaxel and Intravenous Oxaliplatin With Intraperitoneal Docetaxel in Platinum-Sensitive or Platinum-Resistant Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancer.
intravenous docetaxel with intraperitoneal oxaliplatin; intravenous oxaliplatin with intraperitoneal docetaxel

Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Canc Clinical Trial using RAD001; bevacizumab

University of Pittsburgh - Recruiting 18 years or older.
- Phase II Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer An Investigator-initiated, Single-institution Trial at Magee-Womens Hospital.
RAD001; bevacizumab

Ovarian Cancer Clinical Trial using NGR-hTNF; Pegylated liposomal doxorubicin; Doxorubicin

MolMed S.p.A. - Recruiting 18 years or older.
- NGR018: Randomized Phase II Study of NGR-hTNF Plus an Anthracycline Versus an Anthracycline Alone in Platinum-resistant Ovarian Cancer.
NGR-hTNF; Pegylated liposomal doxorubicin; Doxorubicin

Colorectal and Ovarian Cancer Patients With Liver Metastasis Clinical Trial using EMD525797

Merck KGaA - Recruiting 18 years or older.
- A Phase I, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, PD and PK of EMD 525797 Using DCE-MRI as a PK Measure of Response in Colorectal and Ovarian Cancer Patients With Liver Metastases After Failure of Standard Therapy.
EMD525797

Ovarian Cancer Clinical Trial using Ontak DC; DC vaccination; Ontak

Loyola University - Recruiting 18 years or older.
- Defining the Role of CD4+CD25+ Immunoregulatory T-cells in the Treatment of Patients With Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies.
Ontak DC; DC vaccination; Ontak

Genital Diseases, Female, Ovarian Diseases, Ovarian Neoplasms, Fa Clinical Trial using Bevacizumab; Paclitaxel; Carboplatin; specialized pathology review (Germany only)

AGO Study Group - Recruiting 18 years or older.
- A Prospective Randomised Phase III Trial to Evaluate Optimal Treatment Duration of First-line Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Primary Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer.
Bevacizumab; Paclitaxel; Carboplatin; specialized pathology review (Germany only)

Advanced/Recurrent Breast Cancer, Endometrial Cancer, or Ovarian Clinical Trial using Temsirolimus/PLD

Radboud University - Recruiting 18 years or older.
- A Phase Ib Study of Combination of Temsirolimus (Toriselr) and Pegylated Liposomal Doxorubicin (PLD, Doxilr/ Caelyxr) in Advanced or Recurrent Breast, Endometrial and Ovarian Cancer.
Temsirolimus/PLD

Cognitive/Functional Effects, Fallopian Tube Cancer, Ovarian Canc Clinical Trial using systemic chemotherapy; questionnaire administration; assessment of therapy complications; cognitive assessment; quality-of-life assessment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
systemic chemotherapy; questionnaire administration; assessment of therapy complications; cognitive assessment; quality-of-life assessment

Ovarian Cancer Clinical Trial

National Taiwan University Hospital - Recruiting 15 years to 85 years.
- Epidemiology of Ovarian Cancer in Taiwan.

Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovari Clinical Trial using fentanyl citrate; hydromorphone hydrochloride; ropivacaine hydrochloride

National Cancer Institute (NCI) - Recruiting N/A or older.
- Outcomes of Perioperative Epidural Analgesia in Gynecologic Oncology Patients: A Parallel Prospective Cohort and Randomized Clinical Study.
fentanyl citrate; hydromorphone hydrochloride; ropivacaine hydrochloride

Cervical Cancer, Ovarian Cancer, Endometrial Cancer, Choriocarcin Clinical Trial

Huazhong University of Science and Technology - Recruiting 18 years to 75 years.
- A Large Multicentre Clinical Database and Biobank of Patients With Gynecologic Neoplasms.

Ovarian Cancer Clinical Trial using Catumaxomab

Grupo Espa¤ol de Investigaci¢n en Cáncer de Ovario - Recruiting 18 years or older.
- A Phase II of Intraperitoneal Catumaxomab as a Consolidation Therapy in Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma in Second or Third Complete Clinical Disease Remission.
Catumaxomab

Epithelial Ovarian Cancer, Which is Platinum Resistant or Refract Clinical Trial using Pazopanib and Cyclophosphamid

University Hospital Heidelberg - Recruiting 18 years or older.
- A Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer.
Pazopanib and Cyclophosphamid

Breast Cancer, Cervical Cancer, Endometrial Cancer, or Ovarian Ca Clinical Trial using fluorouracil; pegylated liposomal doxorubicin hydrochloride; hyperthermia treatment

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase I-II Trial of Mild Whole-Body Hyperthermia Combined With Liposomal Doxorubicin/5-Fluorouracil in Patients With Advanced Malignancy.
fluorouracil; pegylated liposomal doxorubicin hydrochloride; hyperthermia treatment

Cancer of Cervix, Ovarian Cancer, or Cancer of Endometrium Clinical Trial using Cognitive intervention; Control group; psycho-physiological intervention

Rabin Medical Center - Recruiting 18 years to 70 years.
- Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial.
Cognitive intervention; Control group; psycho-physiological intervention

Ovarian Cancer Clinical Trial using whole abdomen irradiation using IMRT

University of Heidelberg - Recruiting 18 years to 75 years.
- Adjuvant Whole Abdominal Intensity Modulated Radiotherapy (IMRT) for High Risk Stage FIGO III Patients With Ovarian Cancer: Pilot Trial of a Phase I/II Study.
whole abdomen irradiation using IMRT

Ovarian Cancer Clinical Trial using venous puncture

National Taiwan University Hospital - Recruiting 10 years to 90 years.
- The Development of Human Immunologic Assays Specific to Folate Receptor Antigen.
venous puncture

Breast Cancer, or Ovarian Cancer Clinical Trial using Culturally Tailored Genetic Counseling

University of Pennsylvania - Recruiting 18 years to 85 years.
- Genetic Counseling for Breast Cancer Susceptibility in African American Women.
Culturally Tailored Genetic Counseling

Ovarian Cancer Clinical Trial using Find Cancer Associated Antibodies

Lab Discoveries Ltd. - Recruiting 18 years or older.
- Study to Assess the Effectiveness of the CAAb Test With Ovarian Cancer Patients.
Find Cancer Associated Antibodies

Epithelial Ovarian Carcinoma, or Figo Stage IIIC Clinical Trial using hyper thermic chemo + surgery

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 18 years to 65 years.
- Phase II Study of Intra-Peritoneal Hyper-Thermic Chemotherapy as Consolidation Therapy for Advanced Epithelial Ovarian Carcinoma.
hyper thermic chemo + surgery

Ovarian Cancer Clinical Trial

National Taiwan University Hospital - Recruiting 15 years to 90 years.
- .